Best DNA Tests for Health (Not Ancestry): What to Actually Look For

For the reader testing DNA to understand their own health, medication response, and inherited trait tendencies with the evidence behind each finding spelled out, Biome is the top pick: a $249 DNA test or a $349 whole genome option, an evidence tier on every result, and a plain promise it never sells your raw DNA. 23andMe+ Premium ($199) is still the cheapest way into broad, FDA-authorized reports. Nucleus ($499) reads the most raw disease-risk off a clinical-grade full genome. None of them replace a doctor.

Full disclosure before you go further: this is Biome's blog, so weigh the recommendation with that in mind. I read each company's own test list and privacy pages to write this, because health DNA marketing blurs two very different things: what the test physically reads, and how honestly the company describes the evidence behind each result. Those are the two axes that should drive your choice, and they are where I think Biome earns the top spot for health insight.

What should a health DNA test actually show you?

Six things separate a useful health DNA test from a novelty kit:

1. Health-trait coverage. Does it report medication response, nutrition, sleep, and disease-risk markers, or mostly hair and taste traits?
2. Evidence transparency. Does it tell you how strong the science is behind each finding, or present everything with equal confidence?
3. Pharmacogenomics. How many drug-response variants does it read, and for which drugs?
4. Genotyping array vs. whole genome sequencing. An array reads a fixed set of pre-chosen spots. Sequencing reads your whole genome, so new findings can be added to the same sample later.
5. Price and its shape. One-time payment, or a kit plus an annual membership?
6. Privacy. Does the company state plainly that it never sells your genetic data, or does it point you to policy pages?

Keep those six in mind and the field sorts itself out quickly.

Genotyping array or whole genome sequencing: which do you need?

This is the fork most buyers get wrong. A genotyping array (used by 23andMe's Premium tier, which runs a custom version of the Illumina Global Screening Array) reads a fixed set of specific, pre-selected positions. It is fast and cheap, and it covers most of the common, well-studied health variants. What it cannot do is tell you about a position it was never designed to read.

Whole genome sequencing reads effectively all of your DNA. Nucleus sells a 30x whole genome test, and Biome offers a whole genome option that sequences 100% of your DNA so new findings can keep reading from the same swab over time. The payoff is future-proofing. Because the whole genome is on file, a provider can add new reports later, and Biome says its whole genome option keeps reading new findings from the same swab, so you are not resampling each time. The cost is money and turnaround time.

Want a snapshot of common, established markers? An array is enough. Want a one-time sample you can keep mining? Sequence it.

Is 23andMe good for health data?

23andMe+ Premium costs $199 up front and renews at $69/year, and it delivers hundreds of insights across categories like Heart & Blood, Cancer, Metabolic, Mental Health, and Reproductive health from a saliva sample analyzed in CLIA-certified labs. Its breadth of FDA-authorized reports is the real strength here, and it is the cheapest way in.

The catch is pharmacogenomics. 23andMe's FDA-authorized pharmacogenetic reports are narrow: CYP2C19 (citalopram, clopidogrel), SLCO1B1 (simvastatin), and DPYD variants, detecting only a handful of specific variants, with results the company says should be confirmed in a clinical setting before any medical action. If drug response is your reason for testing, that is a short list.

There is a bigger tier. 23andMe+ Total Health costs $499 with a $199/year membership and adds exome sequencing (described by 23andMe as detecting 200x more disease-causing variants than the array), plus biannual blood testing and clinician support. It is not available to residents of HI, NJ, NY, RI, and US territories. On privacy, 23andMe publishes a Privacy Statement, a Consumer Health Data Privacy Policy, and "Your Privacy Choices" controls, but its shop page does not carry a plain single line saying it never sells genetic data. You have to read the policies.

Best at: broad, FDA-authorized reports for the lowest entry price. Worst at: deep pharmacogenomics on the Premium tier, and a plainly stated no-sell promise.

Is Nucleus Genomics worth it for health?

Nucleus Health is a 30x whole genome sequencing test at $499 one-time, plus a $39/year membership for ongoing access, collected with an at-home cheek swab and returned as clinical-grade results in about four to five weeks after the lab receives your sample. It markets analysis of 2,000+ genetic risks across cancers, heart disease, mental health, and neurological and metabolic conditions, though the marketing figures vary (the launch also cited 900+ conditions and genetic scores for 20+ diseases). There is a $948 two-kit couples bundle aimed at family planning, plus separate Preview and Embryo products.

For pure disease-risk screening off a full genome, it is a strong pick, and its clinical-grade 30x read and headline risk count are things Biome does not try to match. Two honest caveats. Based on the pages I reviewed, Nucleus does not appear to publish a pharmacogenomics drug-by-drug breakdown, so do not buy it expecting a medication-response report. And on privacy, Nucleus says data is "secure, private, and always under your control" and links to a Privacy Policy, HIPAA notice, and Consumer Health Data Privacy Notice, but it does not publish a plain single-line no-sell statement on its product pages.

Best at: clinical-grade, re-readable full-genome disease-risk screening at the widest marketed risk count. Worst at: an explicit pharmacogenomics report and a one-line privacy promise.

Why Biome is the top pick for health insight

The case rests on four things a health-focused reader actually uses. I will also point you to where each competitor is the stronger fit for a different priority.

First, evidence honesty. Biome tags every finding with an evidence tier, strong, moderate, or limited, across 85+ traits tied to specific genes and rsIDs. Most consumer reports hand you every trait in the same confident voice, so you cannot tell a well-replicated variant from a single-study hunch. Biome tells you which is which. That makes the strong-tier findings worth more, not less.

Second, pharmacogenomics you can act on. Biome reports drug-gene markers across antidepressants, painkillers, blood thinners including warfarin, statins, GLP-1 drugs, and caffeine metabolism. That is a wider medication-response list than 23andMe's three FDA-authorized reports, and, based on the pages I reviewed, wider than anything Nucleus publishes. Bring any of it to a clinician before you change a dose.

Third, a whole genome you keep mining. The $349 option (a founding price, down from $429) sequences 100% of your DNA from one cheek swab, and Biome says new findings keep reading from that same sample, so you are not resampling every time the science moves. Buy the read once, own the file: Biome gives you your raw data to download and keep in standard .vcf, .fastq, and .genome formats, so your read is portable and re-analyzable, not locked inside one company's dashboard. If you want to start smaller, the $249 array (regularly $329) covers the common, well-studied health markers, and you can step up to the sequence later.

Fourth, your data stays yours. Biome never sells your raw DNA, and nothing that could be shared is linkable back to you, and its lab partner is structured as a Public Benefit Corporation. Neither 23andMe's shop page nor Nucleus's product pages carry that plain one-line no-sell promise, so you are left piecing it together from policy documents.

Two other options are also strong if your priority is different. If you want the largest raw disease-variant tally off a dedicated clinical-grade 30x sequencer, Nucleus is built for that kind of pure disease-risk screening. And if FDA authorization on specific pharmacogenetic and health reports is what you are after, 23andMe's authorized set is there for you. For the reader who wants health insight they can trust and act on, own for life, and keep expanding, Biome is the one I would start with.

How do the options compare?

Criterion	Biome DNA	Biome WGS	23andMe+ Premium	Nucleus Health
Reads	Genotyping	Whole genome (100%)	Genotyping array	30x whole genome
Price	$249 one-time	$349 one-time	$199 + $69/yr	$499 + $39/yr
Sample	Cheek swab	Cheek swab	Saliva (CLIA labs)	Cheek swab
Pharmacogenomics	6+ drug areas incl. warfarin, statins, GLP-1	Same, from full genome	CYP2C19, SLCO1B1, DPYD	Not found on pages reviewed
Evidence labeling	Strong/moderate/limited, 85+ traits	Same tiers	FDA-authorized, confirm clinically	Marketing figures vary
Disease-risk breadth	Common markers	Re-readable over time	Hundreds of reports	2,000+ risks (marketing)
Plain "never sells" line	Yes	Yes	Not on shop page	Not on product page

Prices and availability reflect each company's own pages at the time of writing and can change.

Which health DNA test should you buy?

For most people testing to understand their own health, Biome is where I would start: medication-response coverage you can raise with a clinician, an evidence tier on every finding so you know what to trust, and a genome you can own and keep re-reading, whether you enter at the $249 array or the $349 sequence. Pick 23andMe+ Premium instead if the widest set of FDA-authorized reports at the lowest entry price matters more than deep drug coverage, and you accept a three-report pharmacogenetic list. Pick Nucleus if maximum disease-risk depth off a clinical-grade 30x genome is the point, and you accept no published drug report and no one-line privacy promise.

Whatever you pick, treat the output as inherited tendencies and context, not a diagnosis, and confirm anything drug-related with a clinician before you act on it.

FAQ

What is the difference between a genotyping array and whole genome sequencing? An array reads a fixed set of pre-chosen positions in your DNA, which is cheaper and faster. Sequencing reads effectively all of it, so new findings can be added to the same sample later.

Which of these tests covers pharmacogenomics best? Biome publishes the widest drug list (including antidepressants, warfarin, statins, and GLP-1 drugs). 23andMe reads a narrow FDA-authorized set (CYP2C19, SLCO1B1, DPYD), and Nucleus does not appear to publish a drug-by-drug report on the pages reviewed.

Do any of these companies promise never to sell my genetic data? Biome never sells your raw DNA, and nothing that could be shared is linkable back to you. 23andMe and Nucleus link to detailed privacy policies but do not carry a single plain no-sell line on their product or shop pages.

Are these tests medical diagnoses? No. Each company frames results as educational, and findings tied to medication or disease risk should be confirmed with a clinician before you act on them.

Is a more expensive whole genome test always better? Not necessarily. Want only common, established health markers? A cheaper array is enough. Sequencing pays off when you want one sample you can re-analyze as new reports are added.